Targeting Homologous Recombination Repair in Cancer

DNA Repair in Cancer Therapy

Volumn , Issue , 2012, Pages 119-160

  Willers, Henning ^a   Pfäffle, Heike N ^a   Zou, Lee ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80054723205     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-384999-1.10007-1     Document Type: Chapter

References (409)

1. Ciccia A., Elledge S.J. The DNA damage response: making it safe to play with knives. Mol Cell 2010, 40(2):179-204.
2. San Filippo J., Sung P., Klein H. Mechanism of eukaryotic homologous recombination. Annu Rev Biochem 2008, 77:229-257.
3. West S.C. Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol 2003, 4(6):435-445.
4. Hartlerode A.J., Scully R. Mechanisms of double-strand break repair in somatic mammalian cells. Biochem J 2009, 423(2):157-168.
5. Mimitou E.P., Symington L.S. DNA end resection - unraveling the tail. DNA Repair (Amst) 2011, (in press).
6. You Z., Bailis J.M. DNA damage and decisions: CtIP coordinates DNA repair and cell cycle checkpoints. Trends Cell Biol 2010, 20(7):402-409.
7. Cejka P., Cannavo E., Polaczek P., et al. DNA end resection by Dna2-Sgs1-RPA and its stimulation by Top3-Rmi1 and Mre11-Rad50-Xrs2. Nature 2010, 467(7311):112-116.
8. Niu H., Chung W.H., Zhu Z., et al. Mechanism of the ATP-dependent DNA end-resection machinery from Saccharomyces cerevisiae. Nature 2010, 467(7311):108-111.
9. Nicolette M.L., Lee K., Guo Z., et al. Mre11-Rad50-Xrs2 and Sae2 promote 5' strand resection of DNA double-strand breaks. Nat Struct Mol Biol 2010, 17(12):1478-1485.
10. Shim E.Y., Chung W.H., Nicolette M.L., et al. Saccharomyces cerevisiae Mre11/Rad50/Xrs2 and Ku proteins regulate association of Exo1 and Dna2 with DNA breaks. EMBO J 2010, 29(19):3370-3380.
11. Myers J.S., Cortez D. Rapid activation of ATR by ionizing radiation requires ATM and Mre11. J Biol Chem 2006, 281(14):9346-9350.
12. Jazayeri A., Falck J., Lukas C., et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 2006, 8(1):37-45.
13. Sartori A.A., Lukas C., Coates J., et al. Human CtIP promotes DNA end resection. Nature 2007, 450(7169):509-514.
14. Eid W., Steger M., El-Shemerly M., et al. DNA end resection by CtIP and exonuclease 1 prevents genomic instability. EMBO Rep 2010, 11(12):962-968.
15. Gravel S., Chapman J.R., Magill C., Jackson S.P. DNA helicases Sgs1 and BLM promote DNA double-strand break resection. Genes Dev 2008, 22(20):2767-2772.
16. Zou L. DNA repair: A protein giant in its entirety. Nature 2010, 467(7316):667-668.
17. Thorslund T., McIlwraith M.J., Compton S.A., et al. The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA. Nat Struct Mol Biol 2010, 17(10):1263-1265.
18. Jensen R.B., Carreira A., Kowalczykowski S.C. Purified human BRCA2 stimulates RAD51-mediated recombination. Nature 2010, 467(7316):678-683.
19. Liu J., Doty T., Gibson B., Heyer W.D. Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA. Nat Struct Mol Biol 2010, 17(10):1260-1262.
20. Zhang F., Fan Q., Ren K., Andreassen P.R. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res 2009, 7(7):1110-1118.
21. Sy S.M., Huen M.S., Chen J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci USA 2009, 106(17):7155-7160.
22. Zhang F., Ma J., Wu J., et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol 2009, 19(6):524-529.
23. Wesoly J., Agarwal S., Sigurdsson S., et al. Differential contributions of mammalian Rad54 paralogs to recombination, DNA damage repair, and meiosis. Mol Cell Biol 2006, 26(3):976-989.
24. Heyer W.D., Li X., Rolfsmeier M., Zhang X.P. Rad54: the Swiss Army knife of homologous recombination?. Nucleic Acids Res 2006, 34(15):4115-4125.
25. Lin Z., Kong H., Nei M., Ma H. Origins and evolution of the recA/RAD51 gene family: evidence for ancient gene duplication and endosymbiotic gene transfer. Proc Natl Acad Sci USA 2006, 103(27):10328-10333.
26. Liu Y., Tarsounas M., O'Regan P., West S.C. Role of RAD51C and XRCC3 in genetic recombination and DNA repair. J Biol Chem 2007, 282(3):1973-1979.
27. Gari K., Decaillet C., Stasiak A.Z., Stasiak A., Constantinou A. The Fanconi anemia protein FANCM can promote branch migration of Holliday junctions and replication forks. Mol Cell 2008, 29(1):141-148.
28. Bugreev D.V., Mazina O.M., Mazin A.V. Rad54 protein promotes branch migration of Holliday junctions. Nature 2006, 442(7102):590-593.
29. Bugreev D.V., Brosh R.M., Mazin A.V. RECQ1 possesses DNA branch migration activity. J Biol Chem 2008, 283(29):20231-20242.
30. Raynard S., Zhao W., Bussen W., et al. Functional role of BLAP75 in BLM-topoisomerase III alpha-dependent holliday junction processing. J Biol Chem 2008, 283(23):15701-15708.
31. Munoz I.M., Hain K., Declais A.C., et al. Coordination of structure-specific nucleases by human SLX4/BTBD12 is required for DNA repair. Mol Cell 2009, 35(1):116-127.
32. Fekairi S., Scaglione S., Chahwan C., et al. Human SLX4 is a Holliday junction resolvase subunit that binds multiple DNA repair/recombination endonucleases. Cell 2009, 138(1):78-89.
33. Svendsen J.M., Smogorzewska A., Sowa M.E., et al. Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell 2009, 138(1):63-77.
34. Andersen S.L., Bergstralh D.T., Kohl K.P., LaRocque J.R., Moore C.B., Sekelsky J. Drosophila MUS312 and the vertebrate ortholog BTBD12 interact with DNA structure-specific endonucleases in DNA repair and recombination. Mol Cell 2009, 35(1):128-135.
35. Ip S.C., Rass U., Blanco M.G., Flynn H.R., Skehel J.M., West S.C. Identification of Holliday junction resolvases from humans and yeast. Nature 2008, 456(7220):357-361.
36. Svendsen J.M., Harper J.W. GEN1/Yen1 and the SLX4 complex: Solutions to the problem of Holliday junction resolution. Genes Dev 2010, 24(6):521-536.
37. Lee J.H., Paull T.T. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 2005, 308(5721):551-554.
38. Bakkenist C.J., Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003, 421(6922):499-506.
39. Kozlov S.V., Graham M.E., Jakob B., et al. Autophosphorylation and ATM activation: Additional sites add to the complexity. J Biol Chem 2011, 286:9107-9119.
40. Kozlov S.V., Graham M.E., Peng C., Chen P., Robinson P.J., Lavin M.F. Involvement of novel autophosphorylation sites in ATM activation. EMBO J 2006, 25(15):3504-3514.
41. Shiotani B., Zou L. Single-stranded DNA orchestrates an ATM-to-ATR switch at DNA breaks. Mol Cell 2009, 33(5):547-558.
42. Zou L., Elledge S.J. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 2003, 300(5625):1542-1548.
43. Zhao S., Weng Y.C., Yuan S.S., et al. Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products. Nature 2000, 405(6785):473-477.
44. Gatei M., Young D., Cerosaletti K.M., et al. ATM-dependent phosphorylation of nibrin in response to radiation exposure. Nat Genet 2000, 25(1):115-119.
45. Lim D.S., Kim S.T., Xu B., et al. ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature 2000, 404(6778):613-617.
46. Ababou M., Dutertre S., Lecluse Y., Onclercq R., Chatton B., Amor-Gueret M. ATM-dependent phosphorylation and accumulation of endogenous BLM protein in response to ionizing radiation. Oncogene 2000, 19(52):5955-5963.
47. Di Virgilio M., Ying C.Y., Gautier J. PIKK-dependent phosphorylation of Mre11 induces MRN complex inactivation by disassembly from chromatin. DNA Repair (Amst) 2009, 8(11):1311-1320.
48. Bolderson E., Tomimatsu N., Richard D.J., et al. Phosphorylation of Exo1 modulates homologous recombination repair of DNA double-strand breaks. Nucleic Acids Res 2010, 38(6):1821-1831.
49. You Z., Shi L.Z., Zhu Q., et al. CtIP links DNA double-strand break sensing to resection. Mol Cell 2009, 36(6):954-969.
50. Huen M.S., Sy S.M., Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 2010, 11(2):138-148.
51. Cortez D., Wang Y., Qin J., Elledge S.J. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999, 286(5442):1162-1166.
52. Ruffner H., Joazeiro C.A., Hemmati D., Hunter T., Verma I.M. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci USA 2001, 98(9):5134-5139.
53. Polanowska J., Martin J.S., Garcia-Muse T., Petalcorin M.I., Boulton S.J. A conserved pathway to activate BRCA1-dependent ubiquitylation at DNA damage sites. EMBO J 2006, 25(10):2178-2188.
54. Yu X., Fu S., Lai M., Baer R., Chen J. BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP. Genes Dev 2006, 20(13):1721-1726.
55. Flynn R.L., Zou L.A.T.R. A master conductor of cellular responses to DNA replication stress. Trends Biochem Sci 2011, 36(3):133-140.
56. Sorensen C.S., Hansen L.T., Dziegielewski J., et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005, 7(2):195-201.
57. Shi W., Feng Z., Zhang J., et al. The role of RPA2 phosphorylation in homologous recombination in response to replication arrest. Carcinogenesis 2010, 31(6):994-1002.
58. Feng J., Wakeman T., Yong S., Wu X., Kornbluth S., Wang X.F. Protein phosphatase 2A-dependent dephosphorylation of replication protein A is required for the repair of DNA breaks induced by replication stress. Mol Cell Biol 2009, 29(21):5696-5709.
59. Lee D.H., Pan Y., Kanner S., Sung P., Borowiec J.A., Chowdhury D. A PP4 phosphatase complex dephosphorylates RPA2 to facilitate DNA repair via homologous recombination. Nat Struct Mol Biol 2010, 17(3):365-372.
60. Matsuoka S., Ballif B.A., Smogorzewska A., et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007, 316(5828):1160-1166.
61. Ohouo P.Y., Bastos de Oliveira F.M., Almeida B.S., Smolka M.B. DNA damage signaling recruits the Rtt107-Slx4 scaffolds via Dpb11 to mediate replication stress response. Mol Cell 2010, 39(2):300-306.
62. Yamane K., Wu X., Chen J. A DNA damage-regulated BRCT-containing protein, TopBP1, is required for cell survival. Mol Cell Biol 2002, 22(2):555-566.
63. Kumagai A., Lee J., Yoo H.Y., Dunphy W.G. TopBP1 activates the ATR-ATRIP complex. Cell 2006, 124(5):943-955.
64. Burma S., Chen B.P., Murphy M., Kurimasa A., Chen D.J. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 2001, 276(45):42462-42467.
65. Stiff T., O'Driscoll M., Rief N., Iwabuchi K., Lobrich M., Jeggo P.A. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res 2004, 64(7):2390-2396.
66. Stucki M., Clapperton J.A., Mohammad D., Yaffe M.B., Smerdon S.J., Jackson S.P. MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell 2005, 123(7):1213-1226.
67. Lou Z., Minter-Dykhouse K., Franco S., et al. MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals. Mol Cell 2006, 21(2):187-200.
68. Kolas N.K., Chapman J.R., Nakada S., et al. Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science 2007, 318(5856):1637-1640.
69. Mailand N., Bekker-Jensen S., Faustrup H., et al. RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 2007, 131(5):887-900.
70. Huen M.S., Grant R., Manke I., et al. RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell 2007, 131(5):901-914.
71. Wang B., Elledge S.J. Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage. Proc Natl Acad Sci USA 2007, 104(52):20759-20763.
72. Stewart G.S., Panier S., Townsend K., et al. The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage. Cell 2009, 136(3):420-434.
73. Doil C., Mailand N., Bekker-Jensen S., et al. RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell 2009, 136(3):435-446.
74. Bekker-Jensen S., Rendtlew Danielsen J., Fugger K., et al. HERC2 coordinates ubiquitin-dependent assembly of DNA repair factors on damaged chromosomes. Nat Cell Biol 2010, 12(1):80-86. Suppl pp 1-12.
75. Wang B., Matsuoka S., Ballif B.A., et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007, 316(5828):1194-1198.
76. Kim H., Chen J., Yu X. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 2007, 316(5828):1202-1205.
77. Sobhian B., Shao G., Lilli D.R., et al. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 2007, 316(5828):1198-1202.
78. Kim H., Huang J., Chen J. CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage response. Nat Struct Mol Biol 2007, 14(8):710-715.
79. Liu Z., Wu J., Yu X. CCDC98 targets BRCA1 to DNA damage sites. Nat Struct Mol Biol 2007, 14(8):716-720.
80. Shao G., Patterson-Fortin J., Messick T.E., et al. MERIT40 controls BRCA1-Rap80 complex integrity and recruitment to DNA double-strand breaks. Genes Dev 2009, 23(6):740-754.
81. Feng L., Huang J., Chen J. MERIT40 facilitates BRCA1 localization and DNA damage repair. Genes Dev 2009, 23(6):719-728.
82. Wang B., Hurov K., Hofmann K., Elledge S.J. NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control. Genes Dev 2009, 23(6):729-739.
83. Zhuang J., Jiang G., Willers H., Xia F. Exonuclease function of human Mre11 promotes deletional nonhomologous end joining. J Biol Chem 2009, 284(44):30565-30573.
84. Goodarzi A.A., Noon A.T., Deckbar D., et al. ATM signaling facilitates repair of DNA double-strand breaks associated with heterochromatin. Mol Cell 2008, 31(2):167-177.
85. Ziv Y., Bielopolski D., Galanty Y., et al. Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM- and KAP-1 dependent pathway. Nat Cell Biol 2006, 8(8):870-876.
86. Zha S., Guo C., Boboila C., et al. ATM damage response and XLF repair factor are functionally redundant in joining DNA breaks. Nature 2011, 469(7329):250-254.
87. Helmink B.A., Tubbs A.T., Dorsett Y., et al. H2AX prevents CtIP-mediated DNA end resection and aberrant repair in G1-phase lymphocytes. Nature 2011, 469(7329):245-249.
88. Bouwman P., Aly A., Escandell J.M., et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010, 17(6):688-695.
89. Bunting S.F., Callen E., Wong N., et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010, 141(2):243-254.
90. Beucher A., Birraux J., Tchouandong L., et al. ATM and Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in G2. EMBO J 2009, 28(21):3413-3427.
91. Helleday T., Lo J., van Gent D.C., Engelward B.P. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) 2007, 6(7):923-935.
92. Helleday T., Petermann E., Lundin C., Hodgson B., Sharma R.A. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008, 8(3):193-204.
93. Petermann E., Orta M.L., Issaeva N., Schultz N., Helleday T. Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. Mol Cell 2010, 37(4):492-502.
94. Lomonosov M., Anand S., Sangrithi M., Davies R., Venkitaraman A.R. Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein. Genes Dev 2003, 17(24):3017-3022.
95. Wray J., Liu J., Nickoloff J.A., Shen Z. Distinct RAD51 associations with RAD52 and BCCIP in response to DNA damage and replication stress. Cancer Res 2008, 68(8):2699-2707.
96. Osborn A.J., Elledge S.J., Zou L. Checking on the fork: the DNA-replication stress-response pathway. Trends Cell Biol 2002, 12(11):509-516.
97. Hinz J.M. Role of homologous recombination in DNA interstrand crosslink repair. Environ Mol Mutagen 2010, 51(6):582-603.
98. Kee Y., D'Andrea A.D. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev 2010, 24(16):1680-1694.
99. Kennedy R.D., D'Andrea A.D. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev 2005, 19(24):2925-2940.
100. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007, 8(10):735-748.
101. Smogorzewska A., Matsuoka S., Vinciguerra P., et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 2007, 129(2):289-301.
102. Kim Y., Lach F.P., Desetty R., Hanenberg H., Auerbach A.D., Smogorzewska A. Mutations of the SLX4 gene in Fanconi anemia. Nat Genet 2010, 43(2):142-146.
103. Niedernhofer L.J., Lalai A.S., Hoeijmakers J.H. Fanconi anemia (cross)linked to DNA repair. Cell 2005, 123(7):1191-1198.
104. Digweed M., Rothe S., Demuth I., et al. Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia. Carcinogenesis 2002, 23(7):1121-1126.
105. Garcia-Higuera I., Taniguchi T., Ganesan S., et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001, 7(2):249-262.
106. Wang X., Andreassen P.R., D'Andrea A.D. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol Cell Biol 2004, 24(13):5850-5862.
107. Vaz F., Hanenberg H., Schuster B., et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 2010, 42(5):406-409.
108. Garcia-Higuera I., Taniguchi T., Ganesan S., et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Molecular Cell 2001, 7(2):249-262.
109. Litman R., Peng M., Jin Z., et al. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 2005, 8(3):255-265.
110. Howlett N.G., Taniguchi T., Olson S., et al. Biallelic inactivation of BRCA2 in Fanconi anemia [see comment]. Science 2002, 297(5581):606-609.
111. Hirano S., Yamamoto K., Ishiai M., et al. Functional relationships of FANCC to homologous recombination, translesion synthesis, and BLM. EMBO J 2005, 24(2):418-427.
112. Wilson J.B., Blom E., Cunningham R., Xiao Y., Kupfer G.M., Jones N.J. Several tetratricopeptide repeat (TPR) motifs of FANCG are required for assembly of the BRCA2/D1-D2-G-X3 complex, FANCD2 monoubiquitylation and phleomycin resistance. Mutat Res 2010, 689:12-20.
113. Wilson J.B., Yamamoto K., Marriott A.S., et al. FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3. Oncogene 2008, 27(26):3641-3652.
114. Shen X., Do H., Li Y., et al. Recruitment of fanconi anemia and breast cancer proteins to DNA damage sites is differentially governed by replication. Mol Cell 2009, 35(5):716-723.
115. Bagby G.C., Alter B.P. Fanconi anemia. Semin Hematol 2006, 43(3):147-156.
116. Matsushita N., Kitao H., Ishiai M., et al. A FancD2-monoubiquitin fusion reveals hidden functions of Fanconi anemia core complex in DNA repair. Mol Cell 2005, 19(6):841-847.
117. Medhurst A.L., Laghmani el H., Steltenpool J., et al. Evidence for subcomplexes in the Fanconi anemia pathway. Blood 2006, 108(6):2072-2080.
118. Willers H., Kachnic L.A., Luo C.M., et al. Biomarkers and mechanisms of FANCD2 function. J Biomed Biotechnol 2008, 2008:821-829.
119. Gordon S.M., Alon N., Buchwald M.F.A.N.C.C. FANCE, and FANCD2 form a ternary complex essential to the integrity of the Fanconi anemia DNA damage response pathway. J Biol Chem 2005, 280(43):36118-36125.
120. Howlett N.G., Harney J.A., Rego M.A., Kolling F.W.T., Glover T.W. Functional interaction between the Fanconi Anemia D2 protein and proliferating cell nuclear antigen (PCNA) via a conserved putative PCNA interaction motif. J Biol Chem 2009, 284(42):28935-28942.
121. Kachnic LA, Li L, Fournier L, Willers H. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments. Cancer Lett; 292(1): 73-9.
122. Zhi G., Chen X., Newcomb W., Brown J., Semmes O.J., Kupfer G.M. Purification of FANCD2 sub-complexes. Br J Haematol 2010, 150(1):88-92.
123. Bartek J., Lukas J., Bartkova J. DNA damage response as an anti-cancer barrier: damage threshold and the concept of conditional haploinsufficiency. Cell Cycle 2007, 6(19):2344-2347.
124. Halazonetis T.D., Gorgoulis V.G., Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319(5868):1352-1355.
125. Jackson S.P., Bartek J. The DNA-damage response in human biology and disease. Nature 2009, 461(7267):1071-1078.
126. Moynahan M.E., Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol 2010, 11(3):196-207.
127. Reliene R., Bishop A.J., Schiestl R.H. Involvement of homologous recombination in carcinogenesis. Adv Genet 2007, 58:67-87.
128. Sengupta S., Harris C.C. p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005, 6(1):44-55.
129. Schild D., Wiese C. Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability. Nucleic Acids Res 2010, 38(4):1061-1070.
130. Willers H., Dahm-Daphi J., Powell S.N. Repair of radiation damage to DNA. Br J Cancer 2004, 90(7):1297-1301.
131. Powell S.N., Kachnic L.A. Therapeutic exploitation of tumor cell defects in homologous recombination. Anticancer Agents Med Chem 2008, 8(4):448-460.
132. Hakem R., de la Pompa J.L., Sirard C., et al. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 1996, 85(7):1009-1023.
133. Suzuki A., de la Pompa J.L., Hakem R., et al. Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev 1997, 11(10):1242-1252.
134. Meindl A., Hellebrand H., Wiek C., et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010, 42(5):410-414.
135. Seal S., Thompson D., Renwick A., et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006, 38(11):1239-1241.
136. Rahman N., Seal S., Thompson D., et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007, 39(2):165-167.
137. Walsh T., King M.C. Ten genes for inherited breast cancer. Cancer Cell 2007, 11(2):103-105.
138. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med; 362(20): 1909-19.
139. Merajver S.D., Pham T.M., Caduff R.F., et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet 1995, 9(4):439-443.
140. Futreal P.A., Liu Q., Shattuck-Eidens D., et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994, 266(5182):120-122.
141. Lancaster J.M., Wooster R., Mangion J., et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 1996, 13(2):238-240.
142. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3(6):415-428.
143. Esteller M., Silva J.M., Dominguez G., et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000, 92(7):564-569.
144. Rice J.C., Ozcelik H., Maxeiner P., Andrulis I., Futscher B.W. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 2000, 21(9):1761-1765.
145. Catteau A., Harris W.H., Xu C.F., Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 1999, 18(11):1957-1965.
146. Collins N., Wooster R., Stratton M.R. Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. Br J Cancer 1997, 76(9):1150-1156.
147. Potapova A., Hoffman A.M., Godwin A.K., Al-Saleem T., Cairns P. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res 2008, 68(4):998-1002.
148. van der Groep P., Hoelzel M., Buerger H., Joenje H., de Winter J.P., van Diest P.J. Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer. Breast Cancer Res Treat 2007, 107(1):41-47.
149. Wei M., Xu J., Dignam J., et al. Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat 2008, 111(1):113-120.
150. Tokunaga E., Okada S., Kitao H., et al. Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer. Breast Cancer 2009, Oct 8 [Epub ahead of print].
151. Nakanishi K., Yang Y.G., Pierce A.J., et al. Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc Natl Acad Sci USA 2005, 102(4):1110-1115.
152. Godthelp B.C., Wiegant W.W., Waisfisz Q., et al. Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2. Mutat Res 2006, 594(1-2):39-48.
153. Turner N., Tutt A., Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004, 4(10):814-819.
154. Turner N.C., Reis-Filho J.S. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006, 25(43):5846-5853.
155. Turner N.C., Reis-Filho J.S., Russell A.M., et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007, 26(14):2126-2132.
156. Lambie H., Miremadi A., Pinder S.E., et al. Prognostic significance of BRCA1 expression in sporadic breast carcinomas. J Pathol 2003, 200(2):207-213.
157. Silver D.P., Richardson A.L., Eklund A.C., et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010, 28(7):1145-1153.
158. Graeser M., McCarthy A., Lord C.J., et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010, 16(24):6159-6168.
159. Baldwin R.L., Nemeth E., Tran H., et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 2000, 60(19):5329-5333.
160. Geisler J.P., Hatterman-Zogg M.A., Rathe J.A., Buller R.E. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 2002, 94(1):61-67.
161. Hilton J.L., Geisler J.P., Rathe J.A., Hattermann-Zogg M.A., DeYoung B., Buller R.E. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002, 94(18):1396-1406.
162. Taniguchi T., Tischkowitz M., Ameziane N., et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003, 9(5):568-574.
163. Kachnic L.A., Li L., Fournier L., Willers H. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments. Cancer Lett 2010, 292(1):73-79.
164. Willers H., Kachnic L.A., Luo C.-M., et al. Biomarkers and mechanisms of FANCD2 function. J Biomed Biotechnol 2008, 8:821-829.
165. Pagano G., Degan P., d'Ischia M., et al. Oxidative stress as a multiple effector in Fanconi anaemia clinical phenotype. Eur J Haematol 2005, 75(2):93-100.
166. Pagano G., Youssoufian H. Fanconi anaemia proteins: major roles in cell protection against oxidative damage. Bioessays 2003, 25(6):589-595.
167. Hennessy B.T., Timms K.M., Carey M.S., et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010, 28(22):3570-3576.
168. Hruban R.H., Canto M.I., Goggins M., Schulick R., Klein A.P. Update on familial pancreatic cancer. Adv Surg 2010, 44:293-311.
169. Murphy K.M., Brune K.A., Griffin C., et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002, 62(13):3789-3793.
170. Hahn S.A., Greenhalf B., Ellis I., et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003, 95(3):214-221.
171. Jones S., Hruban R.H., Kamiyama M., et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009, 324(5924):217.
172. van der Heijden M.S., brody J.R., Kern S.E. Functional screen of the Fanconi Anemia pathway in cancer cells by FANCD2 immunoblot. Cancer Biol Ther 2004, 3(6):538-539.
173. Van Der Heijden M.S., Brody J.R., Kern S.E. Functional screen of the fanconi anemia pathway in cancer cells by Fancd2 immunoblot. Cancer Biol Ther 2004, 3(6):534-537.
174. van der Heijden M.S., Yeo C.J., Hruban R.H., Kern S.E. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003, 63(10):2585-2588.
175. Goggins M., Schutte M., Lu J., et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996, 56(23):5360-5364.
176. Rogers C.D., van der Heijden M.S., Brune K., et al. The genetics of FANCC and FANCG in familial pancreatic cancer. Cancer Biol Ther 2004, 3(2):167-169.
177. Taron M., Rosell R., Felip E., et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004, 13(20):2443-2449.
178. Rosell R., Skrzypski M., Jassem E., et al. BRCA1: A novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2007, 2(11). e1129.
179. Marsit C.J., Liu M., Nelson H.H., Posner M., Suzuki M., Kelsey K.T. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2004, 23(4):1000-1004.
180. Lee M.N., Tseng R.C., Hsu H.S., et al. Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin Cancer Res 2007, 13(3):832-838.
181. Wachters F.M., Wong L.S., Timens W., Kampinga H.H., Groen H.J. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 2005, 50(2):211-219.
182. Ferrer M., Span S.W., Vischioni B., et al. FANCD2 expression in advanced non-small-cell lung cancer and response to platinum-based chemotherapy. Clin Lung Cancer 2005, 6(4):250-254.
183. Willers H., Kachnic L.A., Birkelbach M., et al. Detection of homologous recombination defects in NSCLC. J Thorac Oncol 2010, 5(12). (Suppl. 7): S516.
184. Miyagawa K. Clinical relevance of the homologous recombination machinery in cancer therapy. Cancer Sci 2008, 99(2):187-194.
185. Rahn J.J., Adair G.M., Nairn R.S. Multiple roles of ERCC1-XPF in mammalian interstrand crosslink repair. Environ Mol Mutagen 2010, 51(6):567-581.
186. Ding L., Getz G., Wheeler D.A., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455(7216):1069-1075.
187. Scott S.P., Bendix R., Chen P., Clark R., Dork T., Lavin M.F. Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc Natl Acad Sci USA 2002, 99(2):925-930.
188. Zhang J., Ma Z., Treszezamsky A., Powell S.N. MDC1 interacts with Rad51 and facilitates homologous recombination. Nat Struct Mol Biol 2005, 12(10):902-909.
189. Bartkova J., Horejsi Z., Sehested M., et al. DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 2007, 26(53):7414-7422.
190. Kutler D.I., Auerbach A.D., Satagopan J., et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg 2003, 129(1):106-112.
191. Verhagen C.V.M., Hageman F., Balm A., et al. Functional FA pathway deficiency in HNSCC cell lines. Proceedings of the 56th Annual Meeting of the Radiatation Research Society, Maui, HI 2010, 168.
192. Ameziane N., Chen F., Leemans C.R., Brakenhoff R.H., Joenje H. No evidence for FANCF gene silencing in head-and-neck squamous cell carcinomas. Cell Oncol 2009, 31(1):53-56.
193. Burkitt K., Ljungman M. Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines. Cancer Lett 2007, 253(1):131-137.
194. Snyder E.R., Ricker J.L., Chen Z., Waes C.V. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines. Cancer Lett 2007, 245(1-2):75-80.
195. Kutler D.I., Wreesmann V.B., Goberdhan A., et al. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2003, 95(22):1718-1721.
196. Park J.W., Pitot H.C., Strati K., et al. Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer. Cancer Res 2010, 70(23):9959-9968.
197. Offit K., Levran O., Mullaney B., et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 2003, 95(20):1548-1551.
198. Weston V.J., Oldreive C.E., Skowronska A., et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor
199. Rosen E.M., Fan S., Goldberg I.D. BRCA1 and prostate cancer. Cancer Invest 2001, 19(4):396-412.
200. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 2005, 7(2):60.
201. Wong A.K., Ormonde P.A., Pero R., et al. Characterization of a carboxy-terminal BRCA1 interacting protein. Oncogene 1998, 17(18):2279-2285.
202. Hiramoto T., Nakanishi T., Sumiyoshi T., et al. Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer. Oncogene 1999, 18(22):3422-3426.
203. Matsuda M., Miyagawa K., Takahashi M., et al. Mutations in the RAD54 recombination gene in primary cancers. Oncogene 1999, 18(22):3427-3430.
204. Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 2010, 31(6):955-960.
205. Thacker J. The RAD51 gene family, genetic instability and cancer. Cancer Lett 2005, 219(2):125-135.
206. Barker C.A., Powell S.N. Enhancing radiotherapy through a greater understanding of homologous recombination. Semin Radiat Oncol 2010, 20(4):267-273. e3.
207. Plo I., Lopez B. AKT1 represses gene conversion induced by different genotoxic stresses and induces supernumerary centrosomes and aneuploidy in hamster ovary cells. Oncogene 2009, 28(22):2231-2237.
208. Plo I., Laulier C., Gauthier L., Lebrun F., Calvo F., Lopez B.S. AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51. Cancer Res 2008, 68(22):9404-9412.
209. McEllin B., Camacho C.V., Mukherjee B., et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res 2010, 70(13):5457-5464.
210. Mendes-Pereira A.M., Martin S.A., Brough R., et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009, 1(6-7):315-322.
211. Salmena L., Carracedo A., Pandolfi P.P. Tenets of PTEN tumor suppression. Cell 2008, 133(3):403-414.
212. Dedes K.J., Wetterskog D., Mendes-Pereira A.M., et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010, 2(53). 53ra75.
213. Shen W.H., Balajee A.S., Wang J., et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128(1):157-170.
214. Golding S.E., Rosenberg E., Neill S., Dent P., Povirk L.F., Valerie K. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res 2007, 67(3):1046-1053.
215. Chan N., Koritzinsky M., Zhao H., et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 2008, 68(2):605-614.
216. Bindra R.S., Schaffer P.J., Meng A., et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 2004, 24(19):8504-8518.
217. Chan N., Pires I.M., Bencokova Z., et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res 2010, 70(20):8045-8054.
218. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability - an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11(3): 220-8.
219. Klein H.L. The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst) 2008, 7(5):686-693.
220. Slupianek A., Hoser G., Majsterek I., et al. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 2002, 22(12):4189-4201.
221. Mitra A., Jameson C., Barbachano Y., et al. Overexpression of RAD51 occurs in aggressive prostatic cancer. Histopathology 2009, 55(6):696-704.
222. Maacke H., Opitz S., Jost K., et al. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer 2000, 88(6):907-913.
223. Kim P.M., Allen C., Wagener B.M., Shen Z., Nickoloff J.A. Overexpression of human RAD51 and RAD52 reduces double-strand break-induced homologous recombination in mammalian cells. Nucleic Acids Res 2001, 29(21):4352-4360.
224. Flygare J., Falt S., Ottervald J., et al. Effects of HsRad51 overexpression on cell proliferation, cell cycle progression, and apoptosis. Exp Cell Res 2001, 268(1):61-69.
225. Gowen L.C., Johnson B.L., Latour A.M., Sulik K.K., Koller B.H. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet 1996, 12(2):191-194.
226. Powell S.N., Kachnic L.A. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 2003, 22(37):5784-5791.
227. Martin R.W., Orelli B.J., Yamazoe M., Minn A.J., Takeda S., Bishop D.K. RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. Cancer Res 2007, 67(20):9658-9665.
228. Mekeel K.L., Tang W., Kachnic L.A., Luo C.M., DeFrank J.S., Powell S.N. Inactivation of p53 results in high rates of homologous recombination. Oncogene 1997, 14(15):1847-1857.
229. Akyüz N., Boehden G.S., Süsse S., et al. DNA substrate dependence of p53-mediated regulation of double-strand break repair. Mol Cell Biol 2002, 22(17):6306-6317.
230. Linke S.P., Sengupta S., Khabie N., et al. p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination. Cancer Res 2003, 63(10):2596-2605.
231. Saintigny Y., Rouillard D., Chaput B., Soussi T., Lopez B.S. Mutant p53 proteins stimulate spontaneous and radiation-induced intrachromosomal homologous recombination independently of the alteration of the transactivation activity and of the G1 checkpoint. Oncogene 1999, 18(24):3553-3563.
232. Willers H., McCarthy E.E., Wu B., et al. Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control. Oncogene 2000, 19(5):632-639.
233. Yun S., Lie A.C.C., Porter A.C. Discriminatory suppression of homologous recombination by p53. Nucleic Acids Res 2004, 32(22):6479-6489.
234. Sengupta S., Linke S.P., Pedeux R., et al. BLM helicase-dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination. EMBO Journal 2003, 22(5):1210-1222.
235. Romanova L.Y., Willers H., Blagosklonny M.V., Powell S.N. The interaction of p53 with replication protein A mediates suppression of homologous recombination. Oncogene 2004, 23:9025-9033.
236. Stürzbecher H.W., Donzelmann B., Henning W., Knippschild U., Buchhop S. p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO Journal 1996, 15(8):1992-2002.
237. Gatz S.A., Wiesmuller L. p53 in recombination and repair. Cell Death Differ 2006, 13(6):1003-1016.
238. Rajagopalan S., Andreeva A., Rutherford T.J., Fersht A.R. Mapping the physical and functional interactions between the tumor suppressors p53 and BRCA2. Proc Natl Acad Sci USA 2010, 107(19):8587-8592.
239. Arias-Lopez C., Lazaro-Trueba I., Kerr P., et al. p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Rep 2006, 7(2):219-224.
240. Levine A.J., Momand J., Finlay C.A. The p53 tumour suppressor gene. Nature 1991, 351(6326):453-456.
241. Lieberman H.B. DNA damage repair and response proteins as targets for cancer therapy. Curr Med Chem 2008, 15(4):360-367.
242. Evers B., Helleday T., Jonkers J. Targeting homologous recombination repair defects in cancer. Trends Pharmacol Sci 2010, 31(8):372-380.
243. Legerski R.J. Repair of DNA interstrand cross-links during S phase of the mammalian cell cycle. Environ Mol Mutagen 2010, 51(6):540-551.
244. Bizanek R., McGuinness B.F., Nakanishi K., Tomasz M. Isolation and structure of an intrastrand cross-link adduct of mitomycin C and DNA. Biochemistry 1992, 31(12):3084-3091.
245. Kartalou M., Essigmann J.M. Recognition of cisplatin adducts by cellular proteins. Mutat Res 2001, 478(1-2):1-21.
246. De Silva I.U., McHugh P.J., Clingen P.H., Hartley J.A. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res 2002, 30(17):3848-3856.
247. Cepeda V., Fuertes M.A., Castilla J., Alonso C., Quevedo C., Perez J.M. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 2007, 7(1):3-18.
248. Bhattacharyya A., Ear U.S., Koller B.H., Weichselbaum R.R., Bishop D.K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000, 275(31):23899-23903.
249. Saleh-Gohari N., Bryant H.E., Schultz N., Parker K.M., Cassel T.N., Helleday T. Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol Cell Biol 2005, 25(16):7158-7169.
250. Treszezamsky A.D., Kachnic L.A., Feng Z., Zhang J., Tokadjian C., Powell S.N. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res 2007, 67(15):7078-7081.
251. Issaeva N., Thomas H.D., Djureinovic T., et al. 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res 2010, 70(15):6268-6276.
252. Roos W.P., Nikolova T., Quiros S., et al. Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. DNA Repair (Amst) 2009, 8(1):72-86.
253. Kennedy R.D., Quinn J.E., Mullan P.B., Johnston P.G., Harkin D.P. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004, 96(22):1659-1668.
254. Byrski T., Huzarski T., Dent R., et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009, 115(2):359-363.
255. Byrski T., Gronwald J., Huzarski T., et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010, 28(3):375-379.
256. Carey L.A. Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer. J Clin Oncol 2010, 28(3):361-363.
257. Kriege M., Seynaeve C., Meijers-Heijboer H., et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009, 27(23):3764-3771.
258. Bast R.C., Mills G.B. Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol 2010, 28(22):3545-3548.
259. Held K.D., Willers H. Molecular and cellular basis of radiation injury. Human Radiation Injury 2011, 1-13. Lippincott Williams & Wilkins, Philadelphia. D.C. Shrieve, J.S. Loeffler (Eds.).
260. Willers H., Held K.D. Introduction to clinical radiation biology. Hematol Oncol Clin North Am 2006, 20(1):1-24.
261. Ward J.F. DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability. Prog Nucleic Acid Res Mol Biol 1988, 35:95-125.
262. Radford I.R. The level of induced DNA double-strand breakage correlates with cell killing after X-irradiation. Int J Radiat Biol Relat Stud Phys Chem Med 1985, 48(1):45-54.
263. Dahm-Daphi J., Dikomey E., Pyttlik C. Relationship between non-reparable DNA strand breaks and cell survival studied in X-irradiated CHO, CHO K1, xrs1 and xrs5 cells. Int J Radiat Biol 1994, 65(6):657-663.
264. Goodhead D.T. Initial events in the cellular effects of ionizing radiations: clustered damage in DNA. Int J Radiat Biol 1994, 65(1):7-17.
265. Lomax M.E., Cunniffe S., O'Neill P. 8-OxoG retards the activity of the ligase III/XRCC1 complex during the repair of a single-strand break, when present within a clustered DNA damage site. DNA Repair (Amst) 2004, 3(3):289-299.
266. Georgakilas A.G., Bennett P.V., Wilson D.M., Sutherland B.M. Processing of bistranded abasic DNA clusters in gamma-irradiated human hematopoietic cells. Nucleic Acids Res 2004, 32(18):5609-5620.
267. Eot-Houllier G., Eon-Marchais S., Gasparutto D., Sage E. Processing of a complex multiply damaged DNA site by human cell extracts and purified repair proteins. Nucleic Acids Res 2005, 33(1):260-271.
268. Henner W.D., Rodriguez L.O., Hecht S.M., Haseltine W.A. Gamma ray induced deoxyribonucleic acid strand breaks. 3' Glycolate termini. J Biol Chem 1983, 258(2):711-713.
269. Dahm-Daphi J., Hubbe P., Horvath F., et al. Nonhomologous end-joining of site-specific but not of radiation-induced DNA double-strand breaks is reduced in the presence of wild-type p53. Oncogene 2005, 24(10):1663-1672.
270. Sutherland B.M., Bennett P.V., Sutherland J.C., Laval J. Clustered DNA damages induced by x rays in human cells. Radiat Res 2002, 157(6):611-616.
271. Gulston M., Fulford J., Jenner T., de Lara C., O'Neill P. Clustered DNA damage induced by gamma radiation in human fibroblasts (HF19), hamster (V79-4) cells and plasmid DNA is revealed as Fpg and Nth sensitive sites. Nucleic Acids Res 2002, 30(15):3464-3472.
272. Hinz J.M., Yamada N.A., Salazar E.P., Tebbs R.S., Thompson L.H. Influence of double-strand-break repair pathways on radiosensitivity throughout the cell cycle in CHO cells. DNA Repair (Amst) 2005, 4(7):782-792.
273. Takata M., Sasaki M.S., Sonoda E., et al. Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J 1998, 17(18):5497-5508.
274. Rothkamm K., Kruger I., Thompson L.H., Lobrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol 2003, 23(16):5706-5715.
275. Shibata A., Conrad S., Birraux J., et al. Factors determining DNA double-strand break repair pathway choice in G2 phase. EMBO J 2011.
276. Lee S.E., Mitchell R.A., Cheng A., Hendrickson E.A. Evidence for DNA-PK-dependent and -independent DNA double-strand break repair pathways in mammalian cells as a function of the cell cycle. Mol Cell Biol 1997, 17(3):1425-1433.
277. Tamulevicius P., Wang M., Iliakis G. Homology-directed repair is required for the development of radioresistance during S phase: interplay between double-strand break repair and checkpoint response. Radiat Res 2007, 167(1):1-11.
278. Richardson C., Moynahan M.E., Jasin M. Double-strand break repair by interchromosomal recombination: suppression of chromosomal translocations. Genes Dev 1998, 12(24):3831-3842.
279. Johnson R.D., Jasin M. Sister chromatid gene conversion is a prominent double-strand break repair pathway in mammalian cells. EMBO J 2000, 19(13):3398-3407.
280. Xia F., Taghian D.G., DeFrank J.S., et al. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc Natl Acad Sci USA 2001, 98(15):8644-8649.
281. Scully R., Ganesan S., Vlasakova K., Chen J., Socolovsky M., Livingston D.M. Genetic analysis of BRCA1 function in a defined tumor cell line. Molecular Cell 1999, 4:1093-1099.
282. Zhang J., Willers H., Feng Z., et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 2004, 24(2):708-718.
283. Alpert T.E., Haffty B.G. Conservative management of breast cancer in BRCA1/2 mutation carriers. Clin Breast Cancer 2004, 5(1):37-42.
284. Gluckman E. Radiosensitivity in Fanconi anemia: application to the conditioning for bone marrow transplantation. Radiother Oncol 1990, 18. Suppl. 1:88-93.
285. Hows J.M., Chapple M., Marsh J.C., et al. Bone marrow transplantation for Fanconi's anaemia: the Hammersmith experience 1977-89. Bone Marrow Transplant 1989, 4(6):629-634.
286. Alter B.P. Radiosensitivity in Fanconi's anemia patients. Radiother Oncol 2002, 62(3):345-347.
287. Marcou Y., D'Andrea A., Jeggo P.A., Plowman P.N. Normal cellular radiosensitivity in an adult Fanconi anaemia patient with marked clinical radiosensitivity. Radiother Oncol 2001, 60(1):75-79.
288. Bremer M., Schindler D., Gross M., Dork T., Morlot S., Karstens J.H. Fanconi's anemia and clinical radiosensitivity report on two adult patients with locally advanced solid tumors treated by radiotherapy. Strahlenther Onkol 2003, 179(11):748-753.
289. Kalb R., Duerr M., Wagner M., et al. Lack of sensitivity of primary Fanconi's anemia fibroblasts to UV and ionizing radiation. Radiat Res 2004, 161(3):318-325.
290. Arlett C.F., Harcourt S.A. Survey of radiosensitivity in a variety of human cell strains. Cancer Res 1980, 40(3):926-932.
291. Duckworth-Rysiecki G., Taylor A.M. Effects of ionizing radiation on cells from Fanconi's anemia patients. Cancer Res 1985, 45(1):416-420.
292. Fornace A.J., Little J.B., Weichselbaum R.R. DNA repair in a Fanconi's anemia fibroblast cell strain. Biochim Biophys Acta 1979, 561(1):99-109.
293. Weichselbaum R.R., Nove J., Little J.B. X-ray sensitivity of fifty-three human diploid fibroblast cell strains from patients with characterized genetic disorders. Cancer Res 1980, 40(3):920-925.
294. Djuzenova C., Flentje M., Plowman P.N. Radiation response in vitro of fibroblasts from a fanconi anemia patient with marked clinical radiosensitivity. Strahlenther Onkol 2004, 180(12):789-797.
295. Kuhnert V.M., Kachnic L.A., Li L., et al. FANCD2-deficient human fibroblasts are hypersensitive to ionising radiation at oxygen concentrations of 0% and 3% but not under normoxic conditions. Int J Radiat Biol 2009, 85(6):523-531.
296. Sprong D., Janssen H.L., Vens C., Begg A.C. Resistance of hypoxic cells to ionizing radiation is influenced by homologous recombination status. Int J Radiat Oncol Biol Phys 2006, 64(2):562-572.
297. Davies K.J. Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems. IUBMB Life 2000, 50(4-5):279-289.
298. Durante M., Loeffler J.S. Charged particles in radiation oncology. Nat Rev Clin Oncol 2010, 7(1):37-43.
299. Hada M., Sutherland B.M. Spectrum of complex DNA damages depends on the incident radiation. Radiat Res 2006, 165(2):223-230.
300. Kundrat P., Stewart R.D. On the biophysical interpretation of lethal DNA lesions induced by ionising radiation. Radiat Prot Dosimetry 2006, 122(1-4):169-172.
301. Kraft G., Kramer M., Scholz M.L.E.T. Track structure and models. A review. Radiat Environ Biophys 1992, 31(3):161-180.
302. Zafar F., Seidler S.B., Kronenberg A., Schild D., Wiese C. Homologous recombination contributes to the repair of DNA double-strand breaks induced by high-energy iron ions. Radiat Res 2010, 173(1):27-39.
303. Frankenberg-Schwager M., Gebauer A., Koppe C., Wolf H., Pralle E., Frankenberg D. Single-strand annealing, conservative homologous recombination, nonhomologous DNA end joining, and the cell cycle-dependent repair of DNA double-strand breaks induced by sparsely or densely ionizing radiation. Radiat Res 2009, 171(3):265-273.
304. Rostek C., Turner E.L., Robbins M., et al. Involvement of homologous recombination repair after proton-induced DNA damage. Mutagenesis 2008, 23(2):119-129.
305. Dikomey E., Dahm-Daphi J., Brammer I., Martensen R., Kaina B. Correlation between cellular radiosensitivity and non-repaired double-strand breaks studied in nine mammalian cell lines. Int J Radiat Biol 1998, 73(3):269-278.
306. Powell C., Mikropoulos C., Kaye S.B., et al. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat Rev 2010, 36(7):566-575.
307. Bryant H.E., Petermann E., Schultz N., et al. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J 2009, 28(17):2601-2615.
308. Chalmers A.J., Lakshman M., Chan N., Bristow R.G. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol 2010, 20(4):274-281.
309. Dungey F.A., Loser D.A., Chalmers A.J. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 2008, 72(4):1188-1197.
310. Harper J.V., Anderson J.A., O'Neill P. Radiation induced DNA DSBs: Contribution from stalled replication forks?. DNA Repair (Amst) 2010, 9(8):907-913.
311. Noel G., Godon C., Fernet M., Giocanti N., Megnin-Chanet F., Favaudon V. Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol Cancer Ther 2006, 5(3):564-574.
312. Godon C., Cordelieres F.P., Biard D., et al. PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic Acids Res 2008, 36(13):4454-4464.
313. Neijenhuis S., Verwijs-Janssen M., van den Broek L.J., Begg A.C., Vens C. Targeted radiosensitization of cells expressing truncated DNA polymerase Β. Cancer Res 2010, 70(21):8706-8714.
314. Neijenhuis S., Verwijs-Janssen M., Kasten-Pisula U., et al. Mechanism of cell killing after ionizing radiation by a dominant negative DNA polymerase beta. DNA Repair (Amst) 2009, 8(3):336-346.
315. Starcevic D., Dalal S., Sweasy J.B. Is there a link between DNA polymerase beta and cancer?. Cell Cycle 2004, 3(8):998-1001.
316. Yuan Z.M., Huang Y., Ishiko T., et al. Regulation of Rad51 function by c-Abl in response to DNA damage. J Biol Chem 1998, 273(7):3799-3802.
317. Chen G., Yuan S.S., Liu W., et al. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J Biol Chem 1999, 274(18):12748-12752.
318. Yuan S.S., Chang H.L., Lee E.Y. Ionizing radiation-induced Rad51 nuclear focus formation is cell cycle-regulated and defective in both ATM(-/-) and c-Abl(-/-) cells. Mutat Res 2003, 525(1-2):85-92.
319. Shimizu H., Popova M., Fleury F., et al. c-ABL tyrosine kinase stabilizes RAD51 chromatin association. Biochem Biophys Res Commun 2009, 382(2):286-291.
320. Slupianek A., Schmutte C., Tombline G., et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001, 8(4):795-806.
321. Aloyz R., Grzywacz K., Xu Z.Y., Loignon M., Alaoui-Jamali M.A., Panasci L. Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia 2004, 18(3):409-414.
322. Choudhury A., Zhao H., Jalali F., et al. Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Cancer Ther 2009, 8(1):203-213.
323. Russell J.S., Brady K., Burgan W.E., et al. Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 2003, 63(21):7377-7383.
324. Shimamura T., Shapiro G.I. Heat shock protein 90 inhibition in lung cancer. J Thorac Oncol 2008, 3(6 Suppl. 2):S152-S159.
325. Oda T., Hayano T., Miyaso H., Takahashi N., Yamashita T. Hsp90 regulates the Fanconi anemia DNA damage response pathway. Blood 2007, 109(11):5016-5026.
326. Camphausen K., Tofilon P.J. Inhibition of Hsp90: a multitarget approach to radiosensitization. Clin Cancer Res 2007, 13(15 Pt. 1):4326-4330.
327. Noguchi M., Yu D., Hirayama R., et al. Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Biochem Biophys Res Commun 2006, 351(3):658-663.
328. Lee D.H., Goldberg A.L. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998, 8(10):397-403.
329. von Mikecz A. The nuclear ubiquitin-proteasome system. J Cell Sci 2006, 119(Pt. 10):1977-1984.
330. Krogan N.J., Lam M.H., Fillingham J., et al. Proteasome involvement in the repair of DNA double-strand breaks. Mol Cell 2004, 16(6):1027-1034.
331. Blickwedehl J., McEvoy S., Wong I., et al. Proteasomes and proteasome activator 200 kDa (PA200) accumulate on chromatin in response to ionizing radiation. Radiat Res 2007, 167(6):663-674.
332. Jacquemont C., Taniguchi T. Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res 2007, 67(15):7395-7405.
333. Murakawa Y., Sonoda E., Barber L.J., et al. Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells. Cancer Res 2007, 67(18):8536-8543.
334. Shi W., Ma Z., Willers H., et al. Disassembly of MDC1 foci is controlled by ubiquitin-proteasome-dependent degradation. J Biol Chem 2008, 283(46):31608-31616.
335. Roccaro A.M., Vacca A., Ribatti D. Bortezomib in the treatment of cancer. Recent Pat Anticancer Drug Discov 2006, 1(3):397-403.
336. Chirnomas D., Taniguchi T., de la Vega M., et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 2006, 5(4):952-961.
337. Dupre A., Boyer-Chatenet L., Sattler R.M., et al. A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol 2008, 4(2):119-125.
338. Rass E., Grabarz A., Plo I., Gautier J., Bertrand P., Lopez B.S. Role of Mre11 in chromosomal nonhomologous end joining in mammalian cells. Nat Struct Mol Biol 2009, 16(8):819-824.
339. Harari P.M., Allen G.W., Bonner J.A. Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 2007, 25(26):4057-4065.
340. Chinnaiyan P., Huang S., Vallabhaneni G., et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005, 65(8):3328-3335.
341. Ko J.C., Ciou S.C., Jhan J.Y., et al. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells. Mol Cancer Res 2009, 7(8):1378-1389.
342. Nyati M.K., Morgan M.A., Feng F.Y., Lawrence T.S. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006, 6(11):876-885.
343. Ganapathipillai S.S., Medova M., Aebersold D.M., et al. Coupling of mutated Met variants to DNA repair via Abl and Rad51. Cancer Res 2008, 68(14):5769-5777.
344. Welsh J.W., Mahadevan D., Ellsworth R., Cooke L., Bearss D., Stea B. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol 2009, 4:69.
345. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27(32):5459-5468.
346. Kotian S., Liyanarachchi S., Zelent A., Parvin J.D. Histone deacetylases 9 and 10 are required for homologous recombination. J Biol Chem 2011, January 18; doi: 10.1074/jbc.C110.194233.
347. Adimoolam S., Sirisawad M., Chen J., Thiemann P., Ford J.M., Buggy J.J. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci USA 2007, 104(49):19482-19487.
348. Smith J., Tho L.M., Xu N., Gillespie D.A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010, 108:73-112.
349. Morgan M.A., Parsels L.A., Zhao L., et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010, 70(12):4972-4981.
350. Koniaras K., Cuddihy A.R., Christopoulos H., Hogg A., O'Connell M.J. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 2001, 20(51):7453-7463.
351. Holstege H., Joosse S.A., van Oostrom C.T., Nederlof P.M., de Vries A., Jonkers J. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res 2009, 69(8):3625-3633.
352. Chen C.C., Kennedy R.D., Sidi S., Look A.T., D'Andrea A. Chk1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol Cancer 2009, 8:24.
353. Lavin M.F. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008, 9(10):759-769.
354. Bryant H.E., Helleday T. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res 2006, 34(6):1685-1691.
355. Weston VJ, Oldreive CE, Skowronska A, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood116(22): 4578-87.
356. Kennedy R.D., Chen C.C., Stuckert P., et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 2007, 117(5):1440-1449.
357. Anderson V.E., Walton M.I., Eve P.D., et al. CCT241533 Is a potent and selective inhibitor of Chk2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res 2011, 71(2):463-472.
358. Bentzen S.M., Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 2007, 25(26):4096-4103.
359. Chien K.R. Herceptin and the heart-a molecular modifier of cardiac failure. N Engl J Med 2006, 354(8):789-790.
360. Kerkela R., Grazette L., Yacobi R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006, 12(8):908-916.
361. Nanda A., Dias-Santagata D.C., Stubbs H., et al. Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer. Clin Lung Cancer 2008, 9(5):285-287.
362. Tsuboi M., Le Chevalier T. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. Med Oncol 2006, 23(2):161-170.
363. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361(2):123-134.
364. Chemotherapy in non-small cell lung cancer a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995, 311(7010):899-909.
365. Boles N.C., Peddibhotla S., Chen A.J., Goodell M.A., Rosen J.M. Chk1 haploinsufficiency results in anemia and defective erythropoiesis. PLoS One 2010, 5(1). e8581.
366. Alberts B. DNA replication and recombination. Nature 2003, 421(6921):431-435.
367. Huen M.S., Chen J. Assembly of checkpoint and repair machineries at DNA damage sites. Trends Biochem Sci 2010, 35(2):101-108.
368. Warmerdam DO, Kanaar R. Dealing with DNA damage: relationships between checkpoint and repair pathways. Mutat Res704(1-3): 2-11.
369. Golding S.E., Morgan R.N., Adams B.R., Hawkins A.J., Povirk L.F., Valerie K. Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol Ther 2009, 8(8).
370. Yap TA, Sandhu SK, Carden CP, de Bono JS. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin61(1): 31-49.
371. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355(10):983-991.
372. Cobo M., Isla D., Massuti B., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25(19):2747-2754.
373. Lyakhovich A., Surralles J. Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer. Cancer Lett 2006, 232(1):99-106.
374. Lisby M., Barlow J.H., Burgess R.C., Rothstein R. Choreography of the DNA damage response: spatiotemporal relationships among checkpoint and repair proteins. Cell 2004, 118(6):699-713.
375. Bekker-Jensen S., Mailand N. Assembly and function of DNA double-strand break repair foci in mammalian cells. DNA Repair 2010, 9(12):1219-1228.
376. Yuan S.S., Lee S.Y., Chen G., Song M., Tomlinson G.E., Lee E.Y. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res 1999, 59(15):3547-3551.
377. Tarsounas M., Davies D., West S.C. BRCA2-dependent and independent formation of RAD51 nuclear foci. Oncogene 2003, 22(8):1115-1123.
378. Dray E, Etchin J, Wiese C, et al. Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2. Nat Struct Mol Biol 17(10): 1255-9.
379. Tan T.L., Essers J., Citterio E., et al. Mouse Rad54 affects DNA conformation and DNA-damage-induced Rad51 foci formation. Curr Biol 1999, 9(6):325-328.
380. Wiese C., Dray E., Groesser T., et al. Promotion of homologous recombination and genomic stability by RAD51AP1 via RAD51 recombinase enhancement. Mol Cell 2007, 28(3):482-490.
381. Feng Z., Scott S.P., Bussen W., et al. Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proc Natl Acad Sci USA 2011, 108(2):686-691.
382. Tebbs R.S., Hinz J.M., Yamada N.A., et al. New insights into the Fanconi anemia pathway from an isogenic FancG hamster CHO mutant. DNA Repair (Amst) 2005, 4(1):11-22.
383. Scully R., Chen J., Plug A., et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997, 88(2):265-275.
384. Scully R., Chen J., Ochs R.L., et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 1997, 90(3):425-435.
385. Kennedy R.D., D'Andrea A.D. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 2006, 24(23):3799-3808.
386. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998, 273(10):5858-5868.
387. Paull T.T., Rogakou E.P., Yamazaki V., Kirchgessner C.U., Gellert M., Bonner W.M. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000, 10(15):886-895.
388. Redon C.E., Nakamura A.J., Zhang Y.W., et al. Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res 2010, 16(18):4532-4542.
389. Kinner A., Wu W., Staudt C., Iliakis G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 2008, 36(17):5678-5694.
390. Ismail I.H., Hendzel M.J. The gamma-H2A.X: is it just a surrogate marker of double-strand breaks or much more?. Environ Mol Mutagen 2008, 49(1):73-82.
391. Taneja N., Davis M., Choy J.S., et al. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem 2004, 279(3):2273-2280.
392. Crul M., van Waardenburg R.C., Bocxe S., et al. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol 2003, 65(2):275-282.
393. Strumberg D., Pilon A.A., Smith M., Hickey R., Malkas L., Pommier Y. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff. Mol Cell Biol 2000, 20(11):3977-3987.
394. Olive P.L., Banath J.P. Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytometry B Clin Cytom 2009, 76(2):79-90.
395. Asakawa H., Koizumi H., Koike A., et al. Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. Breast Cancer Res 2010, 12(2). R17.
396. Willers H., Taghian A.G., Luo C.-M., Treszezamsky A.D., Sgroi D., Powell S.N. Utility of DNA repair protein foci for the detection of putative BRCA1-pathway defects in breast cancer biopsies. Mol Cancer Res 2009, 7:1304-1309.
397. Kachnic L.A., Fournier L., Gheorghiu L., Rosenberg C., Powell S.N., Willers H. Utility of chemotherapy-induced Rad51 foci for the identification of homologous recombination defects in breast cancer cell lines. Proceedings of the 55th Annual Meeting of the Radiatation Research Society, Savannah, GA 2009, 99.
398. Vaira V, Fedele G, Pyne S, et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci USA107(18): 8352-6.
399. Behbod F., Kittrell F.S., LaMarca H., et al. An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res 2009, 11(5). R66.
400. Mukhopadhyay A, Elattar A, Cerbinskaite A, et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res16(8): 2344-51.
401. Olive P.L., Banuelos C.A., Durand R.E., Kim J.Y., Aquino-Parsons C. Endogenous and radiation-induced expression of gammaH2AX in biopsies from patients treated for carcinoma of the uterine cervix. Radiother Oncol 2010, 94(1):82-89.
402. Banuelos C.A., Banath J.P., Kim J.Y., Aquino-Parsons C., Olive P.L. gammaH2AX expression in tumors exposed to cisplatin and fractionated irradiation. Clin Cancer Res 2009, 15(10):3344-3353.
403. Sedelnikova O.A., Bonner W.M. GammaH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence. Cell Cycle 2006, 5(24):2909-2913.
404. Solier S., Pommier Y. The apoptotic ring: a novel entity with phosphorylated histones H2AX and H2B and activated DNA damage response kinases. Cell Cycle 2009, 8(12):1853-1859.
405. Wang L.H., Pfister T.D., Parchment R.E., et al. Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res 2010, 16(3):1073-1084.
406. Edwards S.L., Brough R., Lord C.J., et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451(7182):1111-1115.
407. Sakai W., Swisher E.M., Karlan B.Y., et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451(7182):1116-1120.
408. Janne P.A. Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. Lung Cancer 2008, 60(Suppl. 2):S3-S9.
409. Swisher E.M., Sakai W., Karlan B.Y., Wurz K., Urban N., Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008, 68(8):2581-2586.